Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients (Ovrescancer)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00930501
First received: June 28, 2009
Last updated: June 29, 2009
Last verified: June 2009

June 28, 2009
June 29, 2009
June 2009
December 2011   (final data collection date for primary outcome measure)
Anti mullerian hormone [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00930501 on ClinicalTrials.gov Archive Site
  • antral follicle count [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • FSH [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • inhibin b [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • menstrual history [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • E2 and prog [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients
Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients

young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.

our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

bloods

Non-Probability Sample

females 5-45 years old

Infertility
Biological: blood tests
time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
Cancer patients
women 5-45 yr olf pre and post chemotherapy
Intervention: Biological: blood tests
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2013
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • all females prior and after chemotherapy

Exclusion Criteria:

  • do not consent
Female
5 Years to 45 Years
No
Contact: Ariel Revel, MD 97226776424 arielr2@hadassah.org.il
Israel
 
NCT00930501
111222
No
Ariel Revel, MD, Hadassah
Hadassah Medical Organization
Not Provided
Not Provided
Hadassah Medical Organization
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP